PegBio Co., Ltd.
PegBio is a Hangzhou-based, Hong Kong-listed (HKEX: 2565) developer of peptide and protein drugs for type 2 diabetes, obesity and MASH. Its lead product, the long-acting GLP-1 agonist visepegenatide (PB-119, brand name Paidakang), is approved in China for type 2 diabetes.
| Headquarters | Hangzhou, China |
|---|---|
| Listing | HKEX:02565 |
| Lead asset / stage | visepegenatide (PB-119) Approved — China (type 2 diabetes) |
| Latest event | Paidakang (visepegenatide injection) was included in the 2026 Chinese expert consensus on nutrient-stimulated hormone receptor agonists. |